MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jgar.2022.11.010

Медицинская библиотека · Journal of global antimicrobial resistance · 2022

Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures.

Gagliardini Roberta, Lorenzini Patrizia, Cozzi-Lepri Alessandro, Tavelli Alessandro, Borghi Vanni, Galli Laura, Tagliaferri Gianmarco, Maggiolo Franco, Mussini Cristina, Castagna Antonella, Monforte Antonella d'Arminio, Antinori Andrea

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Dolutegravir (DTG) +lamivudine (3TC) combination has been found to be as effective as triple therapies, and has been extensively prescribed in clinical practice as a maintenance therapy. We aimed to investigate the effect of previous virological failures (VFs) on virological efficacy.

METHODS

The analysis included data of people living with HIV (PLWH) with HIV-RNA ≤50 copies/mL enrolled in an Italian retrospective multicohort study who were switching to DTG+3TC. Primary endpoint was viral rebound (VR; confirmed HIV-RNA ≥50 copies/mL or single HIV-RNA ≥50 copies/mL followed by change of antiretroviral therapies [ART]). Kaplan-Meier curves were used to estimate probabilities of VR based upon histories of previous VFs (single HIV-RNA ≥1000 copies/mL or confirmed HIV-RNA ≥50 copies/mL). A weighted Cox regression model was fitted to estimate the causal hazard ratio (HR) of history of failure on the risk of VR.

RESULTS

A total of 966 PLWH were included; 20.1% had a history of previous VF. VR was detected in 23 PLWH. The one-year probability was 1.2% (95% confidence interval [CI], 0.2%-2.2%) in PLWH without previous VF and 3.3% (95% CI, 0.4%-6.2%) in those with ≥1 VF (log-rank P = 0.042). By multivariate analysis adjusted for CD4+ cell count at nadir, duration of virological suppression, and mode of HIV transmission, PLWH with ≥1 previous VF had a higher risk of virological rebound than those without previous VF (adjusted hazard ratio 3.06 [95% CI, 1.00-9.44], P = 0.051).

CONCLUSION

Despite the low absolute one-year risk in both groups, real-world data confirmed that PLWH with a previous failure have an increased risk of viral rebound.

Для цитирования: Gagliardini Roberta, Lorenzini Patrizia, Cozzi-Lepri Alessandro, Tavelli Alessandro, Borghi Vanni, Galli Laura, Tagliaferri Gianmarco, Maggiolo Franco, Mussini Cristina, Castagna Antonella, Monforte Antonella d'Arminio, Antinori Andrea. Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures.. Journal of global antimicrobial resistance. 2022. DOI: 10.1016/j.jgar.2022.11.010.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.